Dianthus Therapeutics Shares Climb After Analyst Coverage Boost

Shares of Dianthus Therapeutics (NASDAQ:DNTH) jumped 5.8% after William Blair initiated coverage on the stock with an Outperform rating, marking the 13th buy recommendation the clinical-stage biotech has received. Analyst Mylers Minter led the coverage, assigning a fair value of $47.57 per share, highlighting the company’s potential in the autoimmune space. Dianthus is currently developing […]